A widely anticipated meeting with investors to discuss its RD pipeline may not have the sort of impact that Sanofi had hoped The drug maker attempted to make a splash this morning by touting predictions that  new products that may be introduced by  could generate as much as  billion over the first five years of sales But there was some disappointing news folded into the projections  The growth in the allimportant diabetes business which presently accounts for  of total revenue is expected to be flat or show just slight improvements between  and 